Oxford Cannabinoid Tech.Holdings Director Dealing Update (0188S)
November 11 2021 - 2:00AM
UK Regulatory
TIDMOCTP
RNS Number : 0188S
Oxford Cannabinoid Tech.Holdings
11 November 2021
11 November 2021
Oxford Cannabinoid Technologies Holdings plc
Director Dealing Update
Further to the announcements of 1 November 2021 and 5 November
2021 (the "Announcements"), Oxford Cannabinoid Technologies
Holdings plc (the "Company"), is pleased to announce that the
Charge over the Pledged Shares in connection with the Facility has
been removed.
Words and expressions defined in the Announcements have the same
meaning ascribed to them herein unless the context suggests
otherwise.
A PDMR form is set out below.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 (which forms part of
domestic UK law pursuant to the European Union (Withdrawal) Act
2018).
The Directors of the Company accept responsibility for the
content of this announcement.
Enquiries:
Oxford Cannabinoid Technologies +44 (0)20 3034 2820
Holdings plc john@oxcantech.com
Dr John Lucas (CEO) clarissa@oxcantech.com
Clarissa Sowemimo-Coker (COO)
Cairn Financial Advisers
Emily Staples +44 (0)20 7213 0897
Jo Turner +44 (0) 20 7213 0885
Walbrook PR Limited +44 (0)20 7933 8780
Paul Vann +44 (0)7768 807631
Nicholas Johnson oxcantech@walbrookpr.com
About Oxford Cannabinoid Technologies Holdings Plc :
Oxford Cannabinoid Technologies Holdings plc ("OCTP" or the
Company") is the holding company of Oxford Cannabinoid Technologies
Ltd ("OCT") (together the "Group") , a pharmaceutical company
developing prescription cannabinoid medicines for approval by key
medicines regulatory agencies worldwide and targeting the U$
multi-billion pain market . Cannabinoids are compounds found in the
cannabis plant that have been shown to have a range of therapeutic
effects on the body, including pain relief. The Group has a clearly
defined path to commercialisation, revenues and growth. The Group
is developing drug candidates through clinical trials to gain
regulatory approval (FDA/MHRA/EMA) that will enable medical
professionals to prescribe them with confidence.
The Group's portfolio aims to balance risk, value and time to
market, whilst ensuring market exclusivity around all its key
activities. The Group's lead compound, OCT461201, is a highly
potent and selective CB2 agonist and is being developed by OCT in a
solid oral dosage form. OCT is conducting pre-clinical testing and
development with pre-clinical trials scheduled for 2022. The
Group's product pipeline also uses a balanced drug product strategy
that employs both natural and synthetic compounds for the treatment
of rare diseases and includes chemically modified phytocannabinoids
with improved drug-like characteristics and a proprietary library
of cannabinoids.
OCTP operates a partnership model with external academic and
commercial partners, including the University of Oxford with whom
OCT has had an umbrella research collaboration since 13 March
2018.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
---- -----------------------------------------------------------------------------------------
a. Name Indraneil (Neil) Mahapatra (via control
of voting rights in OCTP held by KCP LLP)
------------------------------------------------------------
2 Reason for notification
--------------------------- ------------------------------------------------------------
a. Position/Status Executive Chairman
--------------------------- ------------------------------------------------------------
b. Initial notification/ Initial notification
Amendment
--------------------------- ------------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------------------
a. Name Oxford Cannabinoid Technologies Holdings
plc (OCTP)
---------------------------
b. LEI 2138005SRWT4998BCE35
--------------------------- ------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------------------
a. Description of Ordinary Shares of GBP0.01
the financial
instrument, type GB00BMVMRB86
of instrument
Identification
Code
--------------------------- ------------------------------------------------------------
b. Nature of the Removal of security over OCTP shares held
transaction by Kingsley Capital Partners (KCP) LLP -
Margin Loan Facility provided by Brown Shipley
& Co Limited.
--------------------------- ------------------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
--------------------------- --------------
Nil 198,466,493
---------------------------------------------------- -------------
d. Aggregated information N/A - Single transaction
- Aggregated Volume
- Price
--------------------------- ------------------------------------------------------------
e. Date of the transaction
10th November 2021
--------------------------- ------------------------------------------------------------
f. Place of the transaction London, UK
--------------------------- ------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHURVRRAAUAAUA
(END) Dow Jones Newswires
November 11, 2021 02:00 ET (07:00 GMT)
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Sep 2023 to Sep 2024